Logos Capital

VC Conj. 62 São Paulo, Brazil ·Founded 2019

Overview

Logos Capital is a fundamental biotechnology-focused investment fund.

Investment Focus

  • Focus on transformative biotechnology companies
  • Preference for companies with innovative therapeutic approaches
  • Interest in both private and public biotechnology firms
  • Emphasis on companies with attractive valuations
  • Alignment with the firm's mission to improve patient lives

Portfolio Companies

AdcendoMirador TherapeuticsAttovia TherapeuticsScorpion TherapeuticsMaze Therapeutics858 TherapeuticsThird Arc BioObsidian TherapeuticsProfoundBioRapport Therapeutics

Reach Logos Capital directly

Verified work email, phone and LinkedIn for the full team — one spreadsheet, one payment, yours to keep.

Unlock full contacts →

Frequently asked questions about Logos Capital

What sectors does Logos Capital invest in?

Logos Capital invests in Healthcare, Biotechnology, Pharmaceutical, Life Science, Oncology and Therapeutics, and is based in Conj. 62 São Paulo, Brazil. Logos Capital is listed as a vc in the ConnectSafely investor database.

What stage does Logos Capital invest at?

Logos Capital backs companies at Seed, Series A and Series B, writing cheques of 500K - 200M.

Which regions does Logos Capital invest in?

Logos Capital invests across United States, United Kingdom, Canada, Singapore, China and Denmark.

What companies has Logos Capital invested in?

Logos Capital's portfolio includes Adcendo, Mirador Therapeutics, Attovia Therapeutics, Scorpion Therapeutics, Maze Therapeutics, 858 Therapeutics, Third Arc Bio and Obsidian Therapeutics.

How do I contact Logos Capital?

Logos Capital's contact details — including LinkedIn — are listed in the ConnectSafely investor database, along with its website and the LinkedIn profiles of the team.

Last updated · Source: ConnectSafely investor database